Both studies coded DCIS lesions with a score of 3+ on immunostaining for HER2/neu as HER2/neu positive but DCIS lesions with equivocal immunostaining for HER2/neu (score of 2+) were scored as positive in the Kerlikowske study. The gene discussed is ERBB2; the disease is ductal breast carcinoma in situ.